標(biāo)題: Titlebook: An Information Technology Framework for Predictive, Preventive and Personalised Medicine; A Use-Case with Hepa Leonard Berliner,Heinz U. Le [打印本頁] 作者: 信賴 時(shí)間: 2025-3-21 18:48
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine影響因子(影響力)
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine影響因子(影響力)學(xué)科排名
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine網(wǎng)絡(luò)公開度
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine被引頻次
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine被引頻次學(xué)科排名
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine年度引用
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine年度引用學(xué)科排名
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine讀者反饋
書目名稱An Information Technology Framework for Predictive, Preventive and Personalised Medicine讀者反饋學(xué)科排名
作者: 枯萎將要 時(shí)間: 2025-3-21 23:32 作者: amorphous 時(shí)間: 2025-3-22 03:50
Book 2015he patient -- functional status, liver function, degree of cirrhosis, and comorbidities; tumor biology, at a molecular, genetic and anatomic level; tumor burden and individual patient response; medical and operative treatments and their outcomes.作者: 苦惱 時(shí)間: 2025-3-22 04:45
https://doi.org/10.1007/978-3-319-12166-6Decision Support System; Hepatocellular Cancer; Information Technology; Model Guided Therapy; Predictive作者: FIN 時(shí)間: 2025-3-22 09:36
978-3-319-38434-4Springer International Publishing Switzerland 2015作者: ENDOW 時(shí)間: 2025-3-22 14:42
Leonard Berliner,Heinz U. LemkeProvides a roadmap for integrating Information Technology with PPPM.Proposes a methodology for managing vast amounts of personal medical data for decision support by means of Bayesian networks.Introdu作者: NIL 時(shí)間: 2025-3-22 17:56 作者: Cumulus 時(shí)間: 2025-3-22 22:16
Annette Bathen,Kerstin Meyer,Fabian Stibaneical practice, and basic medical research could be best served by information technology (IT). To avoid the problems inherent in formulating IT solutions in isolation, a use-case was developed employing hepatocellular carcinoma (HCC). The subject matter was approached from four separate, but interre作者: 步兵 時(shí)間: 2025-3-23 02:43 作者: thalamus 時(shí)間: 2025-3-23 06:46 作者: nominal 時(shí)間: 2025-3-23 09:53 作者: 討好女人 時(shí)間: 2025-3-23 16:43 作者: Harridan 時(shí)間: 2025-3-23 19:01 作者: 箴言 時(shí)間: 2025-3-24 02:01 作者: 畸形 時(shí)間: 2025-3-24 02:53 作者: ATP861 時(shí)間: 2025-3-24 06:33 作者: 袋鼠 時(shí)間: 2025-3-24 11:08 作者: Abduct 時(shí)間: 2025-3-24 16:29
Die Produktivit?t von MusikkulturenT) has historically been a challenge. Although HCC is a radiosensitive tumor, it is surrounded by highly radiosensitive organs, including the remainder of the liver and hollow gastrointestinal viscera. As technology has advanced to the point of allowing a highly conformal dose to be delivered to the作者: Mercurial 時(shí)間: 2025-3-24 19:11 作者: foodstuff 時(shí)間: 2025-3-24 23:16
Die Produktivit?t von Musikkulturenl be presented in the form of expert recommendations and outlook for Predictive, Preventive and Personalized Medicine (PPPM) and hepatocellular carcinoma (HCC). To advance PPPM, the subject of HCC will be presented from a more integrated point of view, combining epidemiology, risk factors, infectiou作者: objection 時(shí)間: 2025-3-25 06:11 作者: Clumsy 時(shí)間: 2025-3-25 08:15
2211-3495 umor biology, at a molecular, genetic and anatomic level; tumor burden and individual patient response; medical and operative treatments and their outcomes.978-3-319-38434-4978-3-319-12166-6Series ISSN 2211-3495 Series E-ISSN 2211-3509 作者: 偏離 時(shí)間: 2025-3-25 14:20 作者: Cuisine 時(shí)間: 2025-3-25 19:14
Annette Bathen,Kerstin Meyer,Fabian Stibaneement of HCC. An IT System for Predictive, Preventive and Personalized Medicine (ITS-PM) for HCC is presented to provide a comprehensive system to provide unified access to general medical and patient-specific information for medical researchers and health care providers from different disciplines i作者: 合法 時(shí)間: 2025-3-25 22:33 作者: nullify 時(shí)間: 2025-3-26 01:34 作者: 我怕被刺穿 時(shí)間: 2025-3-26 06:36
Handwerk als Baustein resilienter St?dte extrahepatic tumor spread. In addition, radiologic assessment of co-morbidities and response to previous treatments must be included in the overall assessment. The patient-specific findings from diagnostic imaging and interventional radiology identified in this chapter will be designated as Informa作者: 使乳化 時(shí)間: 2025-3-26 12:20 作者: Concomitant 時(shí)間: 2025-3-26 14:21
https://doi.org/10.1007/978-3-531-90442-9volves a number of alterations that are genetic and epigenetic such as the activation of cellular oncogenes and the inactivation of tumor suppressor genes. Systemic therapy with single-agent or combination chemotherapy has been studied extensively. However, cytotoxic chemotherapy traditionally has b作者: 粗語 時(shí)間: 2025-3-26 19:52 作者: 先鋒派 時(shí)間: 2025-3-26 22:34 作者: Mercantile 時(shí)間: 2025-3-27 05:06 作者: 脊椎動(dòng)物 時(shí)間: 2025-3-27 05:26
Produktivit?t der Musikkulturen? therapy and may be a more effective treatment for HCC. Further study will be needed to determine the effectiveness of combining RFA and TACE, and in which order. The combination of TACE with antiangiogenic agents, such as sorafenib, is under investigation as well. The use of sorafenib may curtail t作者: 蛙鳴聲 時(shí)間: 2025-3-27 10:49 作者: Thymus 時(shí)間: 2025-3-27 15:22 作者: Strength 時(shí)間: 2025-3-27 21:40 作者: FUSC 時(shí)間: 2025-3-27 22:11 作者: GIBE 時(shí)間: 2025-3-28 02:14 作者: Inflamed 時(shí)間: 2025-3-28 07:12 作者: BIBLE 時(shí)間: 2025-3-28 11:55
Imaging in Hepatocellular Carcinoma: Radiologic Assessment, extrahepatic tumor spread. In addition, radiologic assessment of co-morbidities and response to previous treatments must be included in the overall assessment. The patient-specific findings from diagnostic imaging and interventional radiology identified in this chapter will be designated as Informa作者: 起波瀾 時(shí)間: 2025-3-28 17:08 作者: 不朽中國 時(shí)間: 2025-3-28 20:47
Personalized Chemotherapy for Hepatocellular Carcinoma,volves a number of alterations that are genetic and epigenetic such as the activation of cellular oncogenes and the inactivation of tumor suppressor genes. Systemic therapy with single-agent or combination chemotherapy has been studied extensively. However, cytotoxic chemotherapy traditionally has b作者: 哀悼 時(shí)間: 2025-3-29 02:31
Surgical Treatment for Hepatocellular Carcinoma,ment of choice for patients with compromised liver function (Child-Pugh B/C). The clinical parameters identified in this Chapter will be used to generate Digital Patient Models (DPMs) to facilitate diagnosis, prognosis, and treatment selection, i.e. Model Guided Therapy (MGT). The following have bee作者: CREST 時(shí)間: 2025-3-29 06:28
Minimally Invasive Therapies for Hepatocellular Cancer: Ablation Technologies,s the largest clinical experience and will serve as the prototype for understanding the principles, mechanisms, and methods that have been developed for the treatment of HCC. Ablation is performed with a minimally invasive approach—the effect is delivered interstitially and intratumorally via a devi作者: 做事過頭 時(shí)間: 2025-3-29 10:06 作者: spinal-stenosis 時(shí)間: 2025-3-29 13:19
Minimally Invasive Therapies for Hepatocellular Cancer: Catheter-Directed Therapies, therapy and may be a more effective treatment for HCC. Further study will be needed to determine the effectiveness of combining RFA and TACE, and in which order. The combination of TACE with antiangiogenic agents, such as sorafenib, is under investigation as well. The use of sorafenib may curtail t作者: 指數(shù) 時(shí)間: 2025-3-29 18:43
Radiation Oncology in the Treatment of Hepatocellular Carcinoma,n to be an effective alternative to other ablative procedures in nonsurgical candidates with tumors up to 6?cm in size, including HCC in patients with cirrhosis. Radioembolization involves catheter-based infusion of radioactive particles (such as Yttrium-90-labeled microspheres) targeted at the hepa作者: 不理會(huì) 時(shí)間: 2025-3-29 20:52 作者: 不舒服 時(shí)間: 2025-3-30 02:17
Outlook and Expert Recommendations for Predictive, Preventive and Personalized Medicine and Hepatocion, and treatment of HCC. Through the development of an ITS-PM, it may be possible to provide and validate a new methodology for Evidence-Based Medicine utilizing model theory, i.e. Model-Based Medical Evidence (MBME). The information processed in the development of this book was used to reinforce 作者: 甜得發(fā)膩 時(shí)間: 2025-3-30 07:31 作者: 期滿 時(shí)間: 2025-3-30 11:05
The Digital Patient Model and Model Guided Therapy,nd Personalized Medicine (PPPM). Our approach to the management of medical information is based on model theory that has arisen from a conceptual transformation from image-guided patient management to a model-centric world-view or model-guided patient management. This approach seeks to implement a c
